Novo Nordisk CEO Says Group Doubling Medical Supplies in UK Ahead Of Brexit
Executive Summary
Novo Nordisk's chief says the Danish company is stockpiling medicines in case of "no deal" hard Brexit
You may also be interested in...
UK's No-Deal Brexit Plans Revealed For Pharma Sector
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.
Sanofi Top UK Exec Plans For Hard Brexit, Blasts 'Poor Access' To New Drugs
The managing director for Sanofi in the UK says clinical trials there will become less likely in future if access to innovative drugs doesn't improve, causing comparative standards of care to deteriorate.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.